Resonance Health upgrades its FY26 underlying EBITDA guidance to $2.6 million, driven by operational efficiencies and growth in its Software-as-Medical Devices segment, despite a slight revenue timing delay.
- EBITDA guidance increased 30% to $2.6 million
- Revenue guidance trimmed to $16 million due to timing
- Margin expansion to 16.3% reflects operational leverage
- Growth driven by SaMD segment and clinical trial services
- Medium-term target of $30 million revenue and 25% EBITDA margin
EBITDA Guidance Surges Despite Revenue Timing Shift
Resonance Health Limited (ASX:RHT) has boosted its FY26 underlying EBITDA guidance by 30%, now expecting approximately $2.6 million, up from the $2.0 million forecasted in August 2025. This upgrade comes despite a modest downward revision in revenue guidance to around $16 million from $17 million, primarily due to the timing of revenue recognition linked to a major $13.8 million clinical trial contract. Notably, the bulk of this contract's revenue is anticipated to flow into FY27, reflecting a shift in accounting rather than a loss of business.
The upgraded EBITDA outlook is underpinned by stronger operational performance and improved cost efficiencies, rather than one-off gains. Resonance’s underlying EBITDA margin is now forecast at 16.3%, up from 11.8%, signalling meaningful margin expansion as the company leverages its scale and cost discipline.
SaMD and Clinical Trials Drive Profitability
The Software-as-Medical Devices (SaMD) segment is a key contributor to the improved outlook, particularly through imaging endpoints related to GLP-1 metabolic and obesity clinical trials. This segment has benefited from increased contribution and operating leverage, supporting higher margins. Alongside this, the TrialsWest investigator site network has expanded operational capacity by opening new clinics, further bolstering revenue and profitability.
Resonance Clinical, the company’s contract research organisation (CRO) arm, continues to execute major clinical trial contracts effectively, delivering steady revenue streams. These operational strengths align with the company’s strategy to prioritise higher-margin clinical trial services and SaMD offerings, while maintaining tight cost control.
This performance builds on the company’s recent progress, including a record SaMD forward order pipeline exceeding $10 million and nearing completion of a $13.8 million trial recruitment phase, as detailed in the company’s record SaMD pipeline and clinical trial progress reports.
Medium-Term Ambitions and Technological Investment
Resonance Health is targeting medium-term revenue growth towards $30 million and an underlying EBITDA margin of approximately 25%. The company’s diversified business model, spanning clinical trials, SaMD, and clinical services, supports this ambition. It also benefits from a strong contracted revenue base and ongoing expansion opportunities within the global clinical trial ecosystem.
Investment in automation and AI-driven technologies remains a priority, aiming to enhance scalability and operational efficiency. These initiatives are expected to underpin continued margin expansion as the business scales.
While the revenue timing adjustment tempers near-term top-line visibility, the company’s upgraded profitability outlook suggests that investors should focus on the quality of earnings and operational leverage rather than absolute revenue growth in FY26.
Bottom Line?
Resonance Health’s upgraded EBITDA guidance signals improving operational leverage and margin expansion, though revenue timing shifts warrant close monitoring.
Questions in the middle?
- How will revenue recognition timing impact FY27 earnings visibility?
- What are the risks to sustaining margin expansion beyond FY26?
- How effectively can Resonance scale its SaMD segment amid global competition?